Aytu BioPharma Inc. (NASDAQ:AYTU) Receives $9.83 Consensus Price Target from Analysts

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have been assigned a consensus recommendation of “Hold” from the five research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $9.8333.

AYTU has been the topic of a number of analyst reports. Ascendiant Capital Markets increased their target price on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Wednesday, April 8th.

Institutional Trading of Aytu BioPharma

Several large investors have recently made changes to their positions in AYTU. Persistent Asset Partners Ltd acquired a new stake in shares of Aytu BioPharma during the 3rd quarter worth approximately $117,000. Arete Wealth Advisors LLC acquired a new stake in shares of Aytu BioPharma during the 1st quarter worth approximately $135,000. Two Sigma Investments LP boosted its position in shares of Aytu BioPharma by 96.2% during the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after acquiring an additional 33,701 shares in the last quarter. Diadema Partners LP boosted its position in shares of Aytu BioPharma by 12.1% during the 4th quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock worth $795,000 after acquiring an additional 33,118 shares in the last quarter. Finally, FNY Investment Advisers LLC boosted its position in shares of Aytu BioPharma by 24,207.7% during the 4th quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock worth $82,000 after acquiring an additional 31,470 shares in the last quarter. Institutional investors and hedge funds own 33.49% of the company’s stock.

Aytu BioPharma Stock Performance

Shares of NASDAQ:AYTU opened at $2.17 on Friday. The company’s 50 day moving average price is $2.32 and its two-hundred day moving average price is $2.46. Aytu BioPharma has a 12-month low of $1.65 and a 12-month high of $3.07. The firm has a market cap of $23.28 million, a PE ratio of -0.47 and a beta of 0.24. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%.The business had revenue of $12.41 million for the quarter, compared to analyst estimates of $12.05 million. Equities research analysts predict that Aytu BioPharma will post -0.73 earnings per share for the current year.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.